Why did Arovella Therapeutics (ASX:ALA) appoint an acting CEO?

The Board of Arovella Therapeutics appointed Dr Nicole Van Der Weerden as acting CEO following the resignation and termination of the previous CEO, Dr Michael Baker. This change was formalised after an initial market announcement on May 4.

Who is Dr Nicole Van Der Weerden and what is her background?

Dr Nicole Van Der Weerden is an experienced biotechnology executive who joined Arovella Therapeutics (ASX:ALA) as Chief Operating Officer in 2023. She previously spent 18 years at Hexima in various leadership roles, including CEO and COO.

How does the leadership change affect Arovella Therapeutics’ (ASX:ALA) strategy?

While a CEO transition can create uncertainty, the appointment of an internal candidate like the former COO suggests a focus on operational stability. Dr Van Der Weerden is already integrated into the company’s current strategy, having recently led a senior executive meeting in Dublin.

What are the financial terms of the acting CEO’s appointment?

Dr Van Der Weerden’s salary has been increased to match the former CEO’s remuneration of $386,250 plus superannuation. This adjustment ensures pay parity during her tenure as acting CEO.

What are the key risks for Arovella Therapeutics (ASX:ALA) after this news?

The primary risk is the "key person" risk associated with a sudden leadership change during a pivotal clinical period. While Dr Van Der Weerden is experienced, the termination of the previous CEO and the search for a permanent replacement can cause short-term sentiment volatility.

What is the current market valuation of Arovella Therapeutics (ASX:ALA)?

At the time of the leadership announcement, Arovella Therapeutics’ share price was $0.078. As a micro-cap biotechnology stock, the price is highly sensitive to clinical milestones and executive stability.

Arovella appoints Dr Van Der Weerden as acting CEO

Written by Brie CarterPublished May. 7 2026Last Updated May. 7 2026

Arovella Therapeutics (ASX:ALA) appointed Dr Nicole Van Der Weerden as acting CEO, effective immediately.

The move follows the board's decision to accept the resignation and terminate the employment of former CEO Dr Michael Baker, following an initial market announcement on May 4.

Dr Van Der Weerden, an accomplished biotechnology executive who joined the company as COO in 2023, steps into the role during a pivotal period for the firm’s clinical pipeline.

To ensure parity during this interim period, the Board confirmed that Dr Van Der Weerden’s remuneration will be increased to match the previous CEO’s salary of $386,250 plus superannuation.

Arovella’s Chairman, David Williams, expressed high confidence in her leadership, noting her performance during a recent senior executive strategy meeting at ISCT 2026 in Dublin.

Williams emphasised that the board is committed to providing full support as the search for a permanent successor commences.

Dr Van Der Weerden brings substantial industry expertise to the position, including a 18-year tenure at Hexima where she served in various capacities, including CEO and COO.

At the time of reporting, Arovella Therapeutics’ share price was $0.078.